Aurigene Oncology Reports Results from the P-I (SWASTH) Trial of Ribrecabtagene Autoleucel for Multiple Myeloma in India
Shots:
- Dr. Reddy’s subsidiary, Aurigene Oncology, has reported results from the P-I (SWASTH) clinical evaluation of ribrecabtagene autoleucel for treating r/r multiple myeloma among Indian patients
- Initial results from the first 8 heavily pre-treated patients showed a 100% clinical response, with 62.5% experiencing stringent CR; no high-grade CRS or neurotoxicity was observed. Based on these results, the DCGI has approved the initiation of P-II
- Ribrecabtagene autoleucel (DRL-1801) is an autologous anti-BCMA CAR-T therapy using a humanized single-domain antibody for antigen binding and lentivirus as a vector
Ref: Aurigene | Image: Aurigene
Related News:- Dr. Reddy’s Ituxredi (Biosimilar, MabThera) Receives the CHMP’s Positive Opinion
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
